Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|April 28, 2023

Continuous and Modular Manufacturing Innovations: Discussion with JP Bornholdt (INTERPHEX 2023)

JP Bornholdt, director of modular operations, CRB, discusses continuous and modular manufacturing.

JP Bornholdt, director of modular operations, CRB, and an INTERPHEX Keynote speaker in the Applied Continuous and Modular Manufacturing Innovations session, discusses the impact that continuous manufacturing and modular innovations have on biomanufacturing.

For more INTERPHEX 2023 video content, check this page for updates.


Related to this article

The BioPharm Brief: Cosentyx Approved in Polymyalgia Rheumatica, a Phase 3 Survival Win for an AML Vaccine, and $173 Million for In Vivo Bone Marrow Editing
FDA approves Novartis’ Cosentyx as the first anti-IL-17 biologic for polymyalgia rheumatica, SELLAS Life Sciences’ WT1-targeted peptide vaccine galinpepimut-S meets its overall survival primary endpoint in the phase 3 REGAL trial in AML, and Marrow Therapeutics launches with $173 million to develop bone marrow-targeted genetic medicines.